Edward J. Dulac
Executive VP, CFO & TreasurerMr. Edward J. Dulac, III, also known as Ed,also known as Ed, is Executive Vice President, Chief Financial Officer and Treasurer of Intellia Therapeutics, Inc. from July 22, 2024. He served as Chief Financial Officer at Fate Therapeutics, Inc. since August 17, 2020 until June 2024. Mr. Dulac was a Research A nalyst at Barclays Capital, Research Division. Prior to joining the Fate Therapeutics, Mr. Dulac was Vice President of Business Development & Strategy from May 2017 to February 2020, from April 2016 to May 2017 he served as Head of Portfolio Analytics & Strategy at Celgene including Senior Director of Business Development and Director of Global Marketing from 2012 to 2016 and held roles of increasing responsibility in business development, portfolio development strategy and commercial planning since 2012, at Celgene Corporation, a biotechnology company acquired by Bristol-Myers Squibb in 2019. From 2007 to 2012, Mr. Dulac was a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers, prior to which he worked in corporate finance at Pfizer Inc. Mr. Dulac received a B.S. in Pharmacy from the University of Pittsburgh and an M.B.A. from the Kelley School of Business at Indiana University.
Positions
- Company NameIntellia Therapeutics, Inc.Stock CodeNTLAPositionExecutive VP, CFO & TreasurerColleagues
- JMJohn M. LeonardPresident, CEO & Director
- FAFranciscus A. G. M. VerwielIndependent Chairman of the Board
- BSBirgit SchultesExecutive VP & Chief Scientific Officer
- JEJames E. BastaExecutive VP, General Counsel & Corporate Secretary
- RERachel E. HaurwitzCo-Founder
- JAJennifer A. DoudnaFounder & Member of Scientific Advisor Board
- DJDerrick J. RossiFounder & Member of Scientific Advisor Board
- RBRodolphe BarrangouFounder & Member of Scientific Advisor Board
